E. Masson, Virus de l'immunodéficience humaine : cycle viral et épidémiologie

. Em-consulte, , 2018.

C. Charpentier, F. Damond, F. Brun-vézinet, and D. Descamps, Virus de l'immunodéficience humaine, 2011.

J. Bressy, Prise en charge du VIH -Recommandations du groupe d'experts, 2018.

A. R. Coelho, F. A. Moreira, and A. C. Santos, Diabetes mellitus in HIV-infected patients: fasting glucose, A1c, or oral glucose tolerance test -which method to choose for the diagnosis?, BMC Infect Dis, vol.18, issue.1, p.309, 2018.

, With Special Feature on Prescription Drugs, 2013.

. Hyattsville,

, IDF Diabetes Atlas, 2018.

L. Chiffres-du-diabète-en and F. , , 2018.

J. P. Boyle, T. J. Thompson, E. W. Gregg, L. E. Barker, and D. F. Williamson, Projection of the year 2050 burden of diabetes in the US adult population: dynamic modeling of incidence, mortality, and prediabetes prevalence, Popul Health Metr, vol.8, p.29, 2010.

J. E. Gerich, Insulin resistance is not necessarily an essential component of type 2 diabetes, J Clin Endocrinol Metab, vol.85, issue.6, pp.2113-2118, 2000.

A. Jain and S. Paranjape, Prevalence of type 2 diabetes mellitus in elderly in a primary care facility: An ideal facility, Indian J Endocrinol Metab, vol.17, issue.Suppl1, pp.318-340, 2013.

T. T. Brown, S. R. Cole, and X. Li, Antiretroviral therapy and the prevalence and incidence of diabetes mellitus in the multicenter AIDS cohort study, Arch Intern Med, vol.165, issue.10, pp.1179-84, 2005.

L. Galli, S. Salpietro, and G. Pellicciotta, Risk of type 2 diabetes among HIV-infected and healthy subjects in Italy, Eur J Epidemiol, vol.27, issue.8, pp.657-65, 2012.

A. P. Kourtis, P. Bansil, H. S. Kahn, S. F. Posner, and D. J. Jamieson, Diabetes trends in hospitalized HIV-infected persons in the United States, Curr HIV Res, vol.7, issue.5, pp.481-487, 1994.

N. Friis-møller, C. A. Sabin, R. Weber, A. Monforte, W. M. El-sadr et al., search?client=safari&rls=en&q=Friis-M%C3%B8ller+N,+Sabin+CA,+Weber+R,+d%27Arminio+Monforte+A,+El-Sadr+WM,+Reiss+P,+Thi%C3%A9baut+R,+Morfeldt+L,+De+Wit+S,+Pradier+C,+Calvo+G ,+Law+MG,+Kirk+O,+Phillips+AN,+Lundgren+JD, N Engl J Med, vol.349, issue.21, pp.1993-2003, 2003.

S. W. Worm, D. Wit, S. Weber, and R. , Diabetes mellitus, preexisting coronary heart disease, and the risk of subsequent coronary heart disease events in patients infected with human immunodeficiency virus: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D Study), Circulation, vol.119, issue.6, pp.805-816, 2009.

S. Grinspoon and A. Carr, Cardiovascular risk and body-fat abnormalities in HIV-infected adults, N Engl J Med, vol.352, issue.1, pp.48-62, 2005.

K. Samaras, Prevalence and pathogenesis of diabetes mellitus in HIV-1 infection treated with combined antiretroviral therapy, J Acquir Immune Defic Syndr, vol.50, issue.5, pp.499-505, 1999.

C. Hadigan and S. Kattakuzhy, Diabetes mellitus type 2 and abnormal glucose metabolism in the setting of human immunodeficiency virus, Endocrinol Metab Clin North Am, vol.43, issue.3, pp.685-96, 2014.

J. Capeau, M. Caron, and C. Vigouroux, Les lipodystrophies secondaires aux traitements antirétroviraux de l'infection par le VIH, MS Médecine Sci, vol.22, issue.5, pp.531-537, 2006.

C. Grunfeld, Understanding the complications of antiretroviral drugs, Clin Infect Dis Off Publ Infect Dis Soc Am, vol.47, issue.4, pp.575-581, 2008.

S. G. Deeks, HIV infection, inflammation, immunosenescence, and aging, Annu Rev Med, vol.62, pp.141-55, 2011.

L. H. Kuller, R. Tracy, and W. Belloso, Inflammatory and coagulation biomarkers and mortality in patients with HIV infection, PLoS Med, vol.5, issue.10, p.203, 2008.

T. T. Brown, K. Tassiopoulos, R. J. Bosch, C. Shikuma, and G. A. Mccomsey, Association between systemic inflammation and incident diabetes in HIV-infected patients after initiation of antiretroviral therapy, Diabetes Care, vol.33, issue.10, pp.2244-2253, 2010.

, Actualisation 2015 du rapport Morlat | Corevih IDF Nord, 2018.

A. Tripathi, A. D. Liese, and J. M. Jerrell, Incidence of diabetes mellitus in a population-based cohort of HIV-infected and non-HIV-infected persons: the impact of clinical and therapeutic factors over time, Diabet Med J Br Diabet Assoc, vol.31, issue.10, pp.1185-93, 2014.

, Haute Autorité de Santé -Prévention et dépistage diabète de type 2 & maladies liées au diabète, 2018.

K. Alberti, R. H. Eckel, and S. M. Grundy, Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention

, World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity, American Heart Association, vol.120, issue.16, pp.1640-1645, 2009.

, Les chiffres du diabète en France | Fédération Française des Diabétiques, 2018.

A. C. Hernandez-romieu, S. Garg, E. S. Rosenberg, A. M. Thompson-paul, and J. Skarbinski, Is diabetes prevalence higher among HIV-infected individuals compared with the general population? Evidence from MMP and NHANES 2009-2010, BMJ Open Diabetes Res Care, vol.5, issue.1, p.304, 2017.

L. D. Rasmussen, E. R. Mathiesen, G. Kronborg, C. Pedersen, J. Gerstoft et al., Risk of Diabetes Mellitus in Persons with and without HIV: A Danish Nationwide Population-Based Cohort Study, PLOS ONE, vol.7, issue.9, p.44575, 2012.

N. Srivanich, C. Ngarmukos, and S. Sungkanuparph, Prevalence of and risk factors for prediabetes in HIV-1-infected patients in, J Int Assoc Physicians AIDS Care Chic Ill, vol.9, issue.6, pp.358-61, 2002.

S. Arafath, T. Campbell, J. Yusuff, and R. Sharma, Prevalence of and Risk Factors for Prediabetes in Patients Infected With HIV, Diabetes Spectr, vol.31, issue.2, pp.139-182, 2018.

. Beh_42_43 and . Pdf, , 2018.

L. M. Nix and P. C. Tien, Metabolic syndrome, diabetes, and cardiovascular risk in HIV, Curr HIV/AIDS Rep, vol.11, issue.3, pp.271-279, 2014.

J. S. Currier, J. D. Lundgren, and A. Carr, Epidemiological evidence for cardiovascular disease in HIV-infected patients and relationship to highly active antiretroviral therapy, Circulation, vol.118, issue.2, pp.29-35, 2008.

S. H. Sheth and R. J. Larson, The efficacy and safety of insulin-sensitizing drugs in HIV-associated lipodystrophy syndrome: a meta-analysis of randomized trials, BMC Infect Dis, vol.10, p.183, 2010.

M. A. Noor, R. A. Parker, and E. O'mara, The effects of HIV protease inhibitors atazanavir and lopinavir/ritonavir on insulin sensitivity in HIV-seronegative healthy adults, AIDS Lond Engl, vol.18, issue.16, pp.2137-2181, 2004.

K. D. Erlandson-km and . Tierney-c, Impact of Randomized Antiretroviral Therapy Initiation on Glucose Metabolism: AIDS Clinical Trials Group Study A5224s, AIDS Lond Engl, vol.28, issue.10, pp.1451-61, 2014.

R. J. Ellis, J. Badiee, and F. Vaida, CD4 nadir is a predictor of HIV neurocognitive impairment in the era of combination antiretroviral therapy, AIDS Lond Engl [Internet], vol.25, issue.14, 2011.

J. Capeau, J. Bastard, and M. Caron, VIH, lipodystrophies et troubles métaboliques, Sang Thromb Vaiss, vol.15, issue.9, pp.487-98, 2003.

A. Bigoloni, N. Gianotti, and V. Spagnuolo, Long-term glucose tolerance in highly experienced HIV-infected patients receiving nucleoside analogue-sparing regimens, AIDS Lond Engl, vol.26, issue.14, pp.1837-1877, 2012.